Tagcloud

ACE inhibitor, acetylcholinesterase inhibitor, aciclovir, acne, acute coronary syndrome, acute lymphoblastic leukaemia, ADHD, advanced prostate cancer, advanced renal cell carcinoma, advanced soft tissue sarcoma, adverse reaction, agomelatine, agoraphobia, alendronic acid, alfuzosin, algorithm, aliskiren, allergic rhinitis, allopurinol, alpha1-proteinase inhibitor, Alzheimer's, amantadine hydrochloride, ambrisentan, aminosalicylate, amlodipine, amoxicillin, anaemia, angina pectoris, anidulafungin, ankylosing spondylitis, anti-doping, anti-heparin, anti-human thymocyte immunoglobulin, antibacterial, antibiotic, anticoagulant, antidepressant, antineoplastic, antipsychotic, antiretroviral, antiretroviral therapy, anxiety, aromatase inhibitor, asthma, atazanavir, azacitidine, bacterial infections, BCG Vaccine, beclometasone, behaviour disorders, betamethasone, bevacizumab, bicalutamide, bipolar disorder, bisoprolol fumarate, bisphosphonates, black patients, bladder cancer, bowel cleansing, BPH, breakthrough pain, breast cancer, brinzolamide, bronchospasm, budesonide, bulimia nervosa, calcipotriol, calcium, candesartan, Candida albicans, candidiasis, carbetocin, carbidopa, cardiac insufficiency, cardiovascular disease, cefaclor, ceftriaxone, cefuroxime, cephalosporin, cetirizine, CHF, cholecalciferol, chronic constipation, chronic heart failure, Chronic Kidney Disease, chronic myeloid leukaemia, chronic myelomonocytic leukaemia, chronic pain, chronic pulmonary infection, ciprofloxacin, citalopram hydrobromide, clarithromycin, clavulanic acid, clopidogrel, clotrimazole, clozapine, colorectal cancer, contraception, COPD, coronary artery disease, Crohn’s Disease, cystic fibrosis, dabigatran etexilate, daptomycin, darunavir, dasatinib, degarelix, dementia, depression, dermatophytes, dermatophytose, desogestrel, diabetes, diclofenac, dienogest, diphteria, discontinuations, domperidone, donepezil, doxazosin, doxycycline, drospirenone, duodenal ulcer, dyslipidaemia, eczema, eletriptan, emetogenic cancer chemotherapy, enalapril, endocarditis, entacapone, epigastric bloating, epilepsy, epirubicin, epoetin, ErbB2 (HR2) receptors, erythropoiesis-stimulating agents, esomeprazole, estradiol, ethinylestradiol, etravirine, everolimus, exemestane, faecal impaction, famciclovir, fentanyl, fesoterodine, fever, filgrastim, finasteride, fluconazole, fluoxetine, flurbiprofen, fluvastatin, folate, folic acid, follicular development stimulation, follicular lymphoma, follitropin alpha, fosprepitant, fungal infections, gabapentin, gastric cancer, gastric ulcer, gastroduodenal ulcer, gemcitabine, gestodene, gliclazide, glucosamine sulphate, gonorrhoea, GORD, growth failure, H1N1, hayfever, heart failure, heart rate, Helicobacter pylori, hepatic failure, hepatitis, hepatocellular carcinoma, herpes, hip or knee replacement surgery, hip osteoarthritis, HIV, hyaluronic acid, hydrochlorothiazide, Hylan G-F 20, hypercholesterolaemia, hyperlipidaemia, hyperphosphataemia, hypertension, hyperuricaemia, hypoactive sexual desire disorder, ibritumomab, ibuprofen, IGF-1 deficiency, IMB, immunosuppression, indacaterol, indapamide, infections, inflammation, influenza, insomnia, interferon beta-1a, iobetasol, IOP, ipatropium bromide, irinotecan, Irish Sports Council, ischaemic stroke, isotretinoin, ivabradine, Kaposi's sarcoma, kidney cancer, kidney disease, knee osteoarthritis, lacosamide, lamotrigine, lansoprazole, lapatinib, laropiprant, lenalidomide, lercanidipine, leuprorelin acetate, levodopa, levonorgestrel, liraglutide, lisinopril, losartan, lutropin alpha, Lyme disease, macrogol, magnesium, mania, maraviroc, mecasermin, melatonergic, melatonin, meloxicam, memantine, mesalazine, metastatic colorectal carcinoma, metformin, methadone, methylnaltrexone bromide, methylphenidate hydrochloride, mexiletine hydrochloride, micafungin, migraine, mirtazapine, mixed dyslipidaemia, moxifloxacin, multiple myeloma, multiple sclerosis, muscular disorders, myelodysplastic syndromes, myocardial infarction, naloxone, naratriptan, nasal congestion, nausea, nebivolol, nephropathy, neural tube defects, neutropenia, NICE guidelines, nicotine, nicotinic acid, nilotinib, NSCLC, nutrition, OCD, ocular hypertension, olanzapine, olmesartan, omeprazole, ondensetron, open angle glaucoma, opioid addiction, opioid analgesic, opioid-induced constipation, oseltamivir, osteoarthritis, osteonecrosis of the jaw, osteoporosis, otitis, ovarian cancer, overactive bladder syndrome, oxycodone, paclitaxel, pain, pancreatic cancer, pancreatic exocrine insufficiency, pancreatin, panic disorder, panitumumab, pantoprazole, paracetamol, Parkinson’s, partial-onset seizures, patch, pemetrexed, peptic ulcer, perindopril, peripheral arterial disease, peripheral neuropathic pain, pertussis, piperacillin, Pityriasis versicolor, poliomyelitis, post transplantation hyperlipidaemia, post-operative pain, post-traumatic stress disorder, PPIs, pramipexole, pravastatin, pregnancy, pricing policy, primary hypercholesterolaemia, probiotics, prostate cancer, protamine sulphate, Pseudomonas aeruginosa, psoriasis, psychotic disorders, pulmonary arterial hypertension, pulmonary embolism, quetiapine, raltegravir, ramipril, ranolazine, rasagiline, recombinant IGF-1, reflux oesophagitis, renal disease, renin inhibitor, Restless Legs Syndrome, rheumatoid arthritis, ribavirin, ringworm, risedronate sodium, risperidone, rivaroxaban, rivastigmine, romiplostim, ropinirole, rosacea, RTI, S. aureus, salbutamol, sarcoma, saxagliptin, schizophrenia, SCLC, sertraline, sevelamer carbonate, severe pain, simvastatin, sitagliptin, smoking cessation, sodium alginate, solide organ transplantation, sorafenib, sore throat, spasticity, spinal cord injury, sport, sprain, statins, stroke, strontium ranelate, suicide, systemic embolisation, telmisartan, temsirolimus, terbinafine, testosterone, tetanus, thalidomide, thrombocytopenic purpura, thrush, tibolone, timolol, tinea, tiotropium, tipranavir, tizanidine, tobramycin, tocilizumab, topotecan, trabectedin, tramadol, Trichophyton, trimethoprim, trospium chloride, ustekinumab, UTI, vaccine, valaciclovir, valproate, valsartan, varenicline, venlafaxine, venous thromboembolism, venous thrombosis, vildagliptin, vinorelbine, vitamin D, vomiting, WADA, warfarin, wound, zanamivir, zoledronic acid, Zollinger-Ellison syndrome

MIMS Ireland: New this Month

All entries for New this Month

Lower price of medicines

01 March 2010

MIMS Ireland wish to announce that they have updated a number of prices this month following the 40% reduction of long established medicines starting on the 1st February 2010.... Read more

Clonfolic 0.4mg 28 Pack OTC Only

01 February 2010

Clonmel Healthcare wish to inform you that from 1st February 2010 Clonfolic 0.4mg 28 pack will no longer be available as a GMS reimbursable Product. Clonfolic 0.4mg 28 pack will still be available as an OTC product only. Please rest... Read more

Micardis Now Indicated for Cardiovascular Prevention in High Risk Patients

01 February 2010

Micardis (telmisartan) is now approved by the European Commission for the reduction of cardiovascular (CV) morbidity in patients with manifest atherothrombotic CV disease or type 2 diabetes with documented target organ damage. This new indication is based on a review... Read more

World Anti-Doping Agency announces changes to Prohibited List

04 January 2010

The World Anti-Doping Agency (WADA) has issued a new Prohibited List of Substances and Methods which comes into effect on 1 January 2010. Changes to the Prohibited List are as a result of ongoing reviews by the WADA List and... Read more

New indication for Foznol in Chronic Kidney Disease patients not on dialysis

04 January 2010

Shire Pharmaceuticals Ireland Ltd. have announced that they have received local market approval for an extension to the existing indication for Foznol. This licence extension makes Foznol, the non-calcium, non-resin phosphate binder, available to control hyperphosphataemia in chronic kidney disease... Read more

Amendments to Serenace entry

04 January 2010

MIMS Ireland editorial team wishes to notify you of the update of the entry for Serenace (haloperidol) including all Serenace presentations. Serenace is available as capsules (0.5mg), tablets (1.5mg, 5mg, 10mg, 20mg), as an oral solution (2mg/ml) and a solution... Read more

Transfer of Prostap Marketing Authorisations to Takeda UK

04 August 2009

Wyeth Pharmaceuticals wish to advise of the transfer of the Marketing Authorisations for Prostap 3 and Prostap SR from Wyeth Pharmaceuticals Ltd to Takeda UK Ltd. This change is effective immediately. If you have any supply enquiries, requests for medical... Read more

Strepsils Intensive now available in Honey and Lemon flavour

02 June 2009

Strepsils Intensive 8.75mg lozenges provide patients with a convenient, effective and well-tolerated treatment for sore throat. Strepsils Intensive provides symptomatic relief from a sore throat by coating the throat within two minutes, dissolving in under 10 minutes and providing lasting... Read more

Price adjustment for Efexor/Efexor XL

01 April 2009

Wyeth Pharmaceuticals Ltd. wish to announce that, in accordance with the pricing agreement between IPHA and the HSE, the reimbursement price of Efexor/Efexor XL will be subject to a 20% price reduction effective 1st April 2009. It is important to... Read more

Valeant range of products acquired by MEDA Ireland

02 February 2009

MEDA Ireland wish to announce that they have acquired the Valeant range of products. The MEDA name will begin to appear on the packaging in a phased manner as existing Valeant stock is depleted from the market.... Read more

Changes to Prohibited List Announced by World Anti-Doping Agency

05 January 2009

The new World Anti-Doping Code and accompanying 2009 Prohibited List comes into effect on 1 January 2009. Changes to the List are as a result of stakeholder comments and ongoing reviews by the World Anti-Doping Agency (WADA). Asthmatic patients in... Read more

Price update

05 January 2009

The editorial team wish to announce that prices have been updated for a number of drugs in this issue of MIMS Ireland. This update follows the 2006 agreement between the Irish Pharmaceutical Healthcare Association (IPHA) and the Health Service Executive... Read more

Macrobid 100mg capsules (14 pack) back on the Irish market

05 January 2009

Goldshield Pharmaceuticals are pleased to announce the re-introduction of Macrobid 100mg Capsules (14 pack) to the Irish market.The Product is distributed by Allphar Services Limited.... Read more

New Easy Dosing Syringe for Nurofen For Children Oral Suspension

05 January 2009

Reckitt Benckiser Ireland Ltd is pleased to announce that Nurofen For Children 150ml Oral Suspension is now available with a specifically designed dosage system making it easier for parents to treat pain and fever. Nurofen for Children is a pleasant... Read more

New Pulmicort CFC-free inhaler

05 January 2009

AstraZeneca is pleased to introduce Pulmicort in a new CFC-free inhaler device. Consequently, the following packs have been discontinued: Pulmicort LS inhaler (50mcg)-200 dose, Pulmicort 200mcg-200dose, Pulmicort 200mcg-Hospital Pack-100 dose. These are being replaced by Pulmicort CFC-free Inhaler 100mcg-120 dose,... Read more

New Packaging for Symbicort Turbohaler

01 December 2008

AstraZeneca Pharmaceuticals wish to inform you of a change in packaging for Symbicort Turbohaler (formoterol/budesonide). The new packs are for all strengths of Symbicort (100/6, 200/6, 400/12). Features of the new pack include new font, design and colours that will... Read more

Amoclav 250/125mg new pack size

01 November 2008

Rowex Ltd are pleased to announce the introduction of a new pack size of Amoclav (amoxicillin/clavulanic) 250/125mg film-coated x 21’s. The price of Amoclave 250/125mg x 21’s is €6.08 and as with the other Amoclav presentations, it is reimbursable through... Read more

Champix 4-Week Starter Pack now available

01 November 2008

Pfizer Healthcare Ireland is pleased to announce the introduction of a 4-Week Starter Pack for Champix which is reimbursed under the PCRS scheme from the 1st of September. Champix is indicated for smoking cessation in adults and should be used... Read more

Recall of Ionsys

01 November 2008

Janssen-Cilag Ltd has voluntarily recalled Ionsys, as a precaution, following a suspected product defect of some units in one lot. The defect could potentially result in self activation of the system and an investigation is ongoing to determine the root... Read more

Evorel stock situation

01 October 2008

Janssen-Cilag Ltd. wish to inform you about the current stock situation with Evorel 25 (estradiol patch). Evorel is indicated as, Hormone Replacement Therapy (HRT) for oestrogen deficiency symptoms in peri- and post-menopausal women. Unfortunately there have been problems at the... Read more

Regranex back in stock

01 October 2008

Janssen-Cilag Ltd. wish to inform you that they have received new stock of Regranex (becaplermin) 0.01% gel; therefore they have been able to supply the market once again, since 1st September. Regranex is indicated, in association with other good wound... Read more

Solpadeine capsules - New additional pack size available on GMS

01 September 2008

GlaxoSmithKline Consumer Healthcare (Ireland) Ltd are pleased to announce that Solpadeine Capsules are now available in an additional pack size – 32s. This new pack size will be reimbursed under the GMS scheme from the 1st of September.... Read more

EBIXA – New Once-Daily dosing

01 July 2008

Lundbeck (Ireland) Ltd wish to announce that they received approval from the European Medicines Agency (EMEA) for a new Once-Daily dosing of their NMDA receptor antagonist Ebixa (memantine) for the treatment of moderate to severe Alzheimer’s disease. The approval is... Read more

Change of product name from Laxoberal Liquid to Dulcolax Liquid

01 July 2008

Boehringer Ingelheim wishes to inform you that Laxoberal oral solution is changing name from Laxoberal Liquid 5mg/ml to Dulcolax Liquid in Ireland. There is no change in product composition.... Read more

Change of formulation for Rebif

01 July 2008

Merck Serono wishes to announce that Rebif New Formulation (interferon beta-1a) is now available in Ireland. In a recent 96 week Phase IIIb study, 260 patients with relapsing remitting multiple sclerosis treated with the new formulation experienced a near three-fold... Read more

Debossing of Zoton FasTab

01 July 2008

Wyeth Pharmaceuticals Ltd. would like to inform you of the debossing of Zoton FasTab 15mg oro-dispersible tablets and Zoton FasTab 30mg orodispersible tablets. Zoton FasTab 15mg oro-dispersible tablets will be debossed with 15 on one side; Zoton FasTab 30mg oro-dispersible... Read more

Diamox SR 250mg Capsules

Diamox SR, Goldshield Pharmaceuticals | 01 June 2008

Goldshield Pharmaceuticals are pleased to announce the introduction of Diamox SR 250mg capsules (30 capsules pack) to the Irish market. The product has been available for ordering since 1st May 2008.... Read more

Rivotril Ampoules name change

01 June 2008

Roche Products (Ireland) Limited would like to announce a name change for one of their products. Rivotril Ampoules, formally known as Rivotril Ampoules 1mg/ml concentrate for solution for injection or infusion, will now be known as Rivotril 1mg/ml concentrate for... Read more

MIMS Ireland - Change in Pricing Policy

01 May 2008

Following changes introduced by the HSE for the reimbursement of medicines under the various HSE community schemes, and as MIMS Ireland relies on manufacturers for the prices published with entries, the pricing policy of MIMS Ireland has changed. From May... Read more

New indication for Pemetrexed (Alimta) in combination with cisplatin

01 May 2008

Pemetrexed (Alimta) in combination with cisplatin is now indicated for the 1st line treatment of stage 3B / 4 non small cell lung cancer (NSCLC), other than predominantly squamous cell histology.... Read more

Hospira launches Octreotide solution for injection

01 May 2008

Hospira Ireland Ltd is pleased to announce the launch of Octreotide, the first alternative to Sandostatin available in this market. Octreotide is available in a wide range of presentations: 0.05mg/ml, 0.1mg/ml, 0.2mg/ml, and 0.5mg/ml vials, offering choice, flexibility and convenience.... Read more

Innohep 10 pack launch

01 May 2008

LEO Pharma wishes to announce that the following Innohep syringes have become available in packs of 10 from 1st April 2008: Innohep -10,000 IU in 0.5ml solution for injection, Innohep -14,000 IU in 0.7ml solution for injection and Innohep -18,000... Read more

Innohep 10 pack launch

01 May 2008

LEO Pharma wishes to announce that the following Innohep syringes have become available in packs of 10 from 1st April 2008: Innohep -10,000 IU in 0.5ml solution for injection, Innohep -14,000 IU in 0.7ml solution for injection and Innohep -18,000... Read more

Kelo-cote scar gel available

01 April 2008

Pinewood Healthcare Main Distributor of Kelo-cote scar gel in Ireland As part of Pinewood Healthcare’s continued promise to provide the Irish market with quality products at realistic prices, the company is delighted to announce that it is now the sole... Read more

Anti-doping update

01 March 2008

An athlete wishing to become a bone marrow donor, for which the procedure involves the administration of Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Lenograstim (Granocyte), Molgramsatim (Leucomax) or other granulocyte colony stimulating factor will be required to apply for a standard Therapeutic... Read more

Gygel to replace Ortho-Creme

01 February 2008

Janssen-Cilag Ltd would like to inform you that they have discontinued Gyno- Ortho-Crème (nonoxinol-9) at the end of January 2008. They are pleased to announce that an alternative nonoxinol-9 based spermicidal product will be available from Marlborough Pharmaceuticals Ltd. This... Read more

Efexor XL, Tazicin, Meningitec Suspension

01 February 2008

Wyeth Pharmaceuticals Ltd is pleased to advise you that Efexor XL 37.5mg is now available for the treatment of panic disorder (see New Clinical Evidence). They would also like to inform you that Tazocin (piperacillin/tazobactam) has been reformulated. Tazocin new... Read more

News from the World Anti-Doping Agency

01 January 2008

Changes to Prohibited List announced by World Anti-Doping Agency - The World Anti-Doping Agency (WADA) has issued a new Prohibited List of Substances and Methods which comes into effect on 1 January 2008. Changes to the Prohibited List are as... Read more

New Formulation of Protamine Sulphate

01 January 2008

Launch of Protamine Sulphate 1400 anti heparin IU/ml solution for injection - LEO Pharma is pleased to announce the launch of a new formulation, Protamine Sulphate LEO Pharma 1400 anti heparin IU/ml solution for injection which will be available from... Read more